B. Riley Wealth Advisors Inc. Sells 1,549 Shares of Moderna, Inc. (NASDAQ:MRNA)

B. Riley Wealth Advisors Inc. trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 15.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,322 shares of the company’s stock after selling 1,549 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Moderna were worth $828,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MRNA. Allworth Financial LP boosted its holdings in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association boosted its holdings in shares of Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after buying an additional 102 shares during the period. Sound Income Strategies LLC boosted its holdings in shares of Moderna by 17.8% during the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after buying an additional 115 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after buying an additional 116 shares during the period. Finally, Geo Capital Gestora de Recursos Ltd boosted its holdings in shares of Moderna by 0.4% during the 4th quarter. Geo Capital Gestora de Recursos Ltd now owns 32,339 shares of the company’s stock worth $3,216,000 after buying an additional 144 shares during the period. 75.33% of the stock is owned by institutional investors.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Moderna news, CFO James M. Mock sold 648 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the sale, the chief financial officer now owns 5,726 shares of the company’s stock, valued at approximately $930,303.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 411,255 shares of company stock valued at $55,846,531. 15.70% of the stock is owned by insiders.

Moderna Stock Down 0.7 %

MRNA opened at $133.40 on Friday. The firm’s 50-day simple moving average is $131.68 and its 200-day simple moving average is $110.08. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The firm has a market cap of $51.12 billion, a price-to-earnings ratio of -8.51 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the prior year, the firm earned $0.19 EPS. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. Equities research analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MRNA shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Monday, June 3rd. HSBC reiterated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Royal Bank of Canada upped their target price on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Finally, UBS Group upped their target price on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $129.02.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.